南模生物(688265.SH):目前公司在上海共有6個生產研發基地
格隆匯2月2日丨南模生物(688265.SH)近期在接待機構投資者調研時表示,目前,公司在上海共有6個生產研發基地(半夏路、金科路、哈雷路、金山I期、金山II期、上科路),另有覆蓋華南區域的廣東中山基地與覆蓋華北區域的北京北辰路基地,共計不到14萬個籠位,短期內沒有新增大量產能的計劃,未來將會根據戰略規劃進行部分高成本基地向低成本基地的置換。目前產能利用率約70%,未來會結合下游客户的需求情況進一步優化產能利用率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.